Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-masked, Vehicle-controlled Trial to Evaluate the Safety and Efficacy of ADX-102 Ophthalmic Solution in Subjects With Non-infectious Anterior-uveitis

Next Previous
Trial Profile

A Phase 3, Randomized, Double-masked, Vehicle-controlled Trial to Evaluate the Safety and Efficacy of ADX-102 Ophthalmic Solution in Subjects With Non-infectious Anterior-uveitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Reproxalap (Primary)
  • Indications Anterior uveitis
  • Focus Therapeutic Use
  • Acronyms SOLACE
  • Sponsors Aldeyra Therapeutics

Most Recent Events

  • 25 Jun 2019 Status changed from active, no longer recruiting to completed.
  • 25 Jun 2019 Results presented in the Aldeyra Therapeutics media release.
  • 24 Jun 2019 According to an Aldeyra Therapeutics media release, will hold a webcast and conference call on Tuesday, June 25, 2019 at 8:00 a.m. Eastern Time to provide top-line results from the SOLACE trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top